Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by product launches....
Key Takeaways
- Cipla's September-quarter earnings suffered due to a high base in its US business.
- The company reported sequential growth driven by its strong India business and branded prescription therapies.
- Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth.
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth. Despite declining operating margins, the firm anticipates improvements supported by product launches. Cipla remains focused on evaluating inorganic opportunities to enhance its specialty portfolio.
Original Publisher Attribution
This summary was curated from Economic Times.